Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | MC4R | P32245 | 4/20 | 0.42 |
| ▸ | MC1R | Q01726 | 2/20 | 0.42 |
| ▸ | MC3R | P41968 | 2/20 | 0.42 |
| ▸ | CFD | P00746 | 1/20 | 0.41 |
| ▸ | F12 | P00748 | 3/20 | 0.41 |
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.39 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | TACR1 | P25103 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1379548 | 0.83 | ALDH1A1 (0.50) | ALDH1A1TSHRMC4R | |
| SCHEMBL4033443 | 0.82 | P2RX7 (0.48) | P2RX7MC4RMC1RMC3RCFD | |
| SCHEMBL4032488 | 0.79 | POLB (0.46) | ALDH1A1TSHRCYP2C19SMN1; SMN2CFD | |
| SCHEMBL4034605 | 0.79 | ALDH1A1 (0.48) | P2RX7MAPTALDH1A1TSHRSMN1; SMN2 | |
| SCHEMBL4038814 | 0.78 | AGTR2 (0.44) | ALDH1A1TSHRCYP2C19 | |
| SCHEMBL6980444 | 0.77 | P2RX7 (0.52) | P2RX7MAPTALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL4942705 | 0.77 | P2RX7 (0.52) | P2RX7MAPTALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL4032640 | 0.76 | ALDH1A1 (0.41) | ALDH1A1TSHRMEN1KMT2ATACR1 | |
| SCHEMBL4036580 | 0.71 | ACHE (0.56) | MAPTALDH1A1TSHRCYP2C19SMN1; SMN2 | |
| SCHEMBL6189627 | 0.71 | MMP1 (0.52) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4825664-B2 | — | — | 2011-11-30 | — | — | JP | claimed |
| EP-1592389-B1 | PIPERAZINE-2-CARBOXAMIDE DERIVATIVES | SERONO LAB (CH) | 2009-04-22 | — | — | EP | claimed |
| US-20070142391-A1 | Piperazine-2-carboxamide derivatives | MERCK SERONO SA (CH) | 2007-06-21 | — | — | US | claimed |
| EP-1592389-A2 | PIPERAZINE-2-CARBOXAMIDE DERIVATIVES | Applied Research Systems ARS Holding N.V. (AN) | 2005-11-09 | — | — | EP | claimed |
| WO-2004071390-A2 | PIPERAZINE-2-CARBOXAMIDE DERIVATIVES | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2004-08-26 | — | — | WO | claimed |
| US-8404690-B2 | Piperazine-2-carboxamide derivatives | MERCK SERONO SA (CH) | 2013-03-26 | — | — | US | disclosed |
| EP-1592389-B1 | PIPERAZINE-2-CARBOXAMIDE DERIVATIVES | SERONO LAB (CH) | 2009-04-22 | — | — | EP | disclosed |
| US-20070142391-A1 | Piperazine-2-carboxamide derivatives | MERCK SERONO SA (CH) | 2007-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142391-A1 | Piperazine-2-carboxamide derivatives | P2RX5, P2RX2, NPY5R | P2RX7 31/4885MAPT 4555/4885ALDH1A1 610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.